Table 2.
Quartile of plasma MIC1a |
|||||
---|---|---|---|---|---|
Analysis | 1 | 2 | 3 | 4 | Ptrendb |
All-cause mortality (n=618) | |||||
No. of events/No. at risk | 25/119 | 62/160 | 83/174 | 96/165 | |
Age-adjusted HR (95% CI) | 1 (referent) | 1.88 (1.17–3.03) | 2.51 (1.57–3.99) | 2.85 (1.78–4.58) | <0.0001 |
MV-adjusted HR (95% CI)c | 1 (referent) | 1.77 (1.07–2.91) | 2.55 (1.55–4.19) | 2.63 (1.60–4.32) | 0.0002 |
MV-adjusted HR (95% CI)d | 1 (referent) | 1.74 (1.06–2.88) | 2.54 (1.54–4.19) | 2.63 (1.60–4.32) | 0.0002 |
CRC-specific mortality (n=618) | |||||
No. of events/No. at risk | 19/119 | 43/160 | 59/174 | 57/165 | |
Age-adjusted HR (95% CI) | 1 (referent) | 1.94 (1.12–3.37) | 2.64 (1.54–4.51) | 2.73 (1.57–4.75) | 0.003 |
MV-adjusted HR (95% CI)c | 1 (referent) | 1.65 (0.92–2.94) | 2.60 (1.45–4.67) | 2.34 (1.30–4.21) | 0.01 |
MV-adjusted HR (95% CI)d | 1 (referent) | 1.67 (0.93–3.00) | 2.67 (1.49–4.80) | 2.40 (1.33–4.34) | 0.009 |
Quartiles of plasma MIC1 were defined by the distribution among control individuals without CRC in our previous study.9 We assigned participants to quartile categories based upon cohort-specific cutpoints (NHS: Q1 <565; Q2 565–747, Q3 748–953, Q4 >953 pg/mL) (HPFS: Q1 <610; Q2 610–825; Q3 826–1060; Q4 >1060 pg/mL).
Tests for linear trend were conducted using the median values for each quartile of MIC1.
Additionally adjusted for the following potential confounders: cohort (sex); date of blood draw; race; body mass index (BMI) at the time of blood draw; physical activity (in MET-hours/week) at the time of blood draw; family history of CRC at time of blood draw; regular use of aspirin or NSAIDs at the time of blood draw; stage at diagnosis; history of polyps at the time of blood draw; grade (poor/unknown vs. well vs. moderate) at diagnosis; and anatomic tumor location (colon vs. rectum) at diagnosis
Multivariate models additionally adjusted for the plasma inflammatory markers CRP and IL6 as continuous measures as well as the factors listed in c